Long-term proliferation of immature hypoxia-dependent JMML cells supported by a 3D in vitro system

Blood Advances, ISSN: 2473-9529, Vol: 7, Issue: 8, Page: 1513-1524
2023
  • 2
    Citations
  • 0
    Usage
  • 13
    Captures
  • 1
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

Most Recent News

Long-term proliferation of immature hypoxia-dependent JMML cells supported by a 3D in vitro system

Citation Alice Cani, Caterina Tretti Parenzan, chiara frasson, Elena Rampazzo, Pamela Scarparo, Samuela Francescato, Federico Caicci, Vito Barbieri, Antonio Rosato, Simone Cesaro, Marco Zecca, Concetta

Article Description

Juvenile myelomonocytic leukemia (JMML) is a rare clonal stem cell disorder that occurs in early childhood and is characterized by the hyperactivation of the RAS pathway in 95% of the patients. JMML is characterized by a hyperproliferation of granulocytes and monocytes, and little is known about the heterogeneous nature of leukemia-initiating cells, as well as of the cellular hierarchy of the JMML bone marrow. In this study, we report the generation and characterization of a novel patient-derived three-dimensional (3D) in vitro JMML model, called patient-derived JMML Atypical Organoid (pd-JAO), sustaining the long-term proliferation of JMML cells with stem cell features and patient-specific hallmarks. JMML cells brewed in a 3D model under different microenvironmental conditions acquired proliferative and survival advantages when placed under low oxygen tension. Transcriptomic and microscopic analyses revealed the activation of specific metabolic energy pathways and the inactivation of processes leading to cell death. Furthermore, we demonstrated the pd-JAO–derived cells’ migratory, propagation, and self-renewal capacities. Our study contributes to the development of a robust JMML 3D in vitro model for studying and defining the impact of microenvironmental stimuli on JMML disease and the molecular mechanisms that regulate JMML initiating and propagating cells. Pd-JAO may become a promising model for compound tests focusing on new therapeutic interventions aimed at eradicating JMML progenitors and controlling JMML disease.

Bibliographic Details

Cani, Alice; Tretti Parenzan, Caterina; Frasson, Chiara; Rampazzo, Elena; Scarparo, Pamela; Francescato, Samuela; Caicci, Federico; Barbieri, Vito; Rosato, Antonio; Cesaro, Simone; Zecca, Marco; Micalizzi, Concetta; Sainati, Laura; Pigazzi, Martina; Biffi, Alessandra; Buldini, Barbara; Locatelli, Franco; Persano, Luca; Masetti, Riccardo; Te Kronnie, Geertruij; Bresolin, Silvia

American Society of Hematology

Medicine

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know